In the first clinical trial to examine the effect of direct inhibition of IL-1 upon markers of CKD-MBD, we found no change in any circulating markers of mineral metabolism, including 25(OH)D, 1,25(OH)2D, and FGF23. This evidence concerns the gene FGF23 and Marchiafava-Bignami disease.